berberine has been researched along with Fatty Liver in 20 studies
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To explore the therapeutic effect and the hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease." | 9.15 | [Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease]. ( Kong, H; Meng, X; Shu, X; Xie, X; Zhou, X, 2011) |
| "Berberine, a natural compound extracted from several Chinese herbs including Coptis chinensis, has been shown to have anti-obesity effects and prevents insulin resistance in high-fat diet (HFD)-fed obese rats by modulating the gut microbiota; however, the molecular mechanisms underlying these activities remain unknown." | 7.88 | Berberine Modulates Gut Microbiota and Reduces Insulin Resistance via the TLR4 Signaling Pathway. ( Hou, L; Li, S; Liu, D; Liu, Y; Tian, H; Zhang, Y; Zhao, T, 2018) |
| "To explore the effect of berberine on lipid metabolism disorder and lipid deposition in liver cells of non-alcoholic fatty liver disease (NAFLD) rats induced by high fat diet." | 7.81 | [Intervention of berberine on lipid deposition in liver cells of non-alcoholic fatty liver disease rats induced by high fat diet]. ( Gong, XW; Han, L; Jin, L; Liang, YJ; Liu, YZ; Wang, PP; Yan, HZ; Yang, QH; Zhang, YP; Zhu, XF, 2015) |
| "To observe the effect of berberine on uncoupling protein-2 (UCP2) mRNA and protein expressions in the hepatic tissue of non-alcoholic fatty liver disease (NAFLD) in rats, and to explore the molecular mechanism." | 7.77 | Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-alcoholic fatty liver disease in rats. ( Chen, TY; Hu, SP; Ji, GY; Li, N; Lin, XF; Liu, HT; Qiao, NL; Xie, WN; Yang, QH; Zhang, YP, 2011) |
| "This study was performed to investigate the molecular mechanism and the therapeutic effect of berberine on nonalcoholic fatty liver disease (NAFLD)." | 7.77 | Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. ( Hua, YQ; Ji, G; Liu, T; Xing, LJ; Zhang, L; Zheng, PY, 2011) |
| " Recently, it has been demonstrated that berberine (BBR) exerts antiobesity and antidiabetic effects in obese and diabetic rodent models through the activation of AMPK in peripheral tissues." | 7.75 | Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. ( Cha, SH; Choe, SS; Jeong, HW; Kim, JB; Kim, WS; Lane, MD; Lee, KU; Lee, MR; Lee, YS; Oh, GT; Park, HS, 2009) |
| "To explore the therapeutic effect and the hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease." | 5.15 | [Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease]. ( Kong, H; Meng, X; Shu, X; Xie, X; Zhou, X, 2011) |
| " Berberine (BBR) is the main bioactive ingredient extracted from traditional Chinese medicines, such as Coptis and Scutellaria, which protect liver function and relieve liver steatosis." | 4.31 | Berberine Ameliorates Abnormal Lipid Metabolism via the Adenosine Monophosphate-Activated Protein Kinase/Sirtuin 1 Pathway in Alcohol-Related Liver Disease. ( Cheng, M; Huang, C; Jia, PC; Li, HD; Li, J; Li, JJ; Liu, JY; Lv, XW; Niu, XN; Xu, JJ; Zhu, L, 2023) |
| "Berberine (BBR), a natural compound extracted from Chinese herb, has been shown to effectively attenuate nonalcoholic fatty liver disease (NAFLD) in clinic." | 3.91 | Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. ( Bian, H; Chang, X; Gao, X; Li, X; Li, Y; Lu, Y; Sun, X; Wang, L; Xia, M; Xia, P; Xu, X; Yan, H; Zhu, X, 2019) |
| "Berberine, a natural compound extracted from several Chinese herbs including Coptis chinensis, has been shown to have anti-obesity effects and prevents insulin resistance in high-fat diet (HFD)-fed obese rats by modulating the gut microbiota; however, the molecular mechanisms underlying these activities remain unknown." | 3.88 | Berberine Modulates Gut Microbiota and Reduces Insulin Resistance via the TLR4 Signaling Pathway. ( Hou, L; Li, S; Liu, D; Liu, Y; Tian, H; Zhang, Y; Zhao, T, 2018) |
| " Berberine (BBR) has been reported to improve insulin sensitivity in mice with hepatic steatosis." | 3.88 | Berberine Protects against NEFA-Induced Impairment of Mitochondrial Respiratory Chain Function and Insulin Signaling in Bovine Hepatocytes. ( Du, XL; Fang, ZY; Fu, SP; Li, XB; Li, XW; Liu, GW; Peng, ZC; Shi, Z; Wang, Z; Zhao, CX, 2018) |
| "To explore the effect of berberine on lipid metabolism disorder and lipid deposition in liver cells of non-alcoholic fatty liver disease (NAFLD) rats induced by high fat diet." | 3.81 | [Intervention of berberine on lipid deposition in liver cells of non-alcoholic fatty liver disease rats induced by high fat diet]. ( Gong, XW; Han, L; Jin, L; Liang, YJ; Liu, YZ; Wang, PP; Yan, HZ; Yang, QH; Zhang, YP; Zhu, XF, 2015) |
| "To observe the effect of berberine on uncoupling protein-2 (UCP2) mRNA and protein expressions in the hepatic tissue of non-alcoholic fatty liver disease (NAFLD) in rats, and to explore the molecular mechanism." | 3.77 | Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-alcoholic fatty liver disease in rats. ( Chen, TY; Hu, SP; Ji, GY; Li, N; Lin, XF; Liu, HT; Qiao, NL; Xie, WN; Yang, QH; Zhang, YP, 2011) |
| "This study was performed to investigate the molecular mechanism and the therapeutic effect of berberine on nonalcoholic fatty liver disease (NAFLD)." | 3.77 | Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. ( Hua, YQ; Ji, G; Liu, T; Xing, LJ; Zhang, L; Zheng, PY, 2011) |
| " Recently, it has been demonstrated that berberine (BBR) exerts antiobesity and antidiabetic effects in obese and diabetic rodent models through the activation of AMPK in peripheral tissues." | 3.75 | Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. ( Cha, SH; Choe, SS; Jeong, HW; Kim, JB; Kim, WS; Lane, MD; Lee, KU; Lee, MR; Lee, YS; Oh, GT; Park, HS, 2009) |
| "Berberine is a Chinese herbal medicine extracted from rhizoma coptidis that functions to improve insulin resistance, hyperlipidemia, hepatosteatosis and inflammation." | 1.48 | Berberine induces miR-373 expression in hepatocytes to inactivate hepatic steatosis associated AKT-S6 kinase pathway. ( Chen, Y; Jiang, JD; Li, CH; Tang, SC; Wang, Y; Wong, CH, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 16 (80.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, L | 1 |
| Xu, JJ | 1 |
| Li, HD | 1 |
| Li, JJ | 1 |
| Cheng, M | 1 |
| Niu, XN | 1 |
| Jia, PC | 1 |
| Liu, JY | 1 |
| Huang, C | 1 |
| Lv, XW | 1 |
| Li, J | 1 |
| Zhang, N | 1 |
| Sheng, M | 1 |
| Wu, M | 1 |
| Zhang, X | 1 |
| Ding, Y | 1 |
| Lin, Y | 1 |
| Yu, W | 1 |
| Wang, S | 1 |
| Du, H | 1 |
| Sun, Y | 1 |
| Xia, M | 2 |
| Yan, H | 3 |
| Han, Y | 1 |
| Zhang, F | 1 |
| Hu, Z | 1 |
| Cui, A | 1 |
| Ma, F | 1 |
| Liu, Z | 1 |
| Gong, Q | 1 |
| Chen, X | 1 |
| Gao, J | 1 |
| Bian, H | 2 |
| Tan, Y | 1 |
| Li, Y | 2 |
| Gao, X | 3 |
| Liu, D | 1 |
| Zhang, Y | 1 |
| Liu, Y | 1 |
| Hou, L | 1 |
| Li, S | 1 |
| Tian, H | 1 |
| Zhao, T | 1 |
| Li, CH | 1 |
| Tang, SC | 1 |
| Wong, CH | 1 |
| Wang, Y | 1 |
| Jiang, JD | 3 |
| Chen, Y | 1 |
| Shi, Z | 1 |
| Li, XB | 1 |
| Peng, ZC | 1 |
| Fu, SP | 1 |
| Zhao, CX | 1 |
| Du, XL | 1 |
| Fang, ZY | 1 |
| Wang, Z | 1 |
| Liu, GW | 1 |
| Li, XW | 1 |
| Yue, SJ | 1 |
| Liu, J | 1 |
| Wang, AT | 1 |
| Meng, XT | 1 |
| Yang, ZR | 1 |
| Peng, C | 1 |
| Guan, HS | 1 |
| Wang, CY | 1 |
| Yan, D | 1 |
| Zhu, X | 1 |
| Wang, L | 2 |
| Sun, X | 1 |
| Xu, X | 1 |
| Chang, X | 2 |
| Lu, Y | 1 |
| Xia, P | 1 |
| Li, X | 1 |
| Cicero, AF | 1 |
| Rosticci, M | 1 |
| Parini, A | 1 |
| Morbini, M | 1 |
| Urso, R | 1 |
| Grandi, E | 1 |
| Borghi, C | 1 |
| Han, L | 1 |
| Yang, QH | 2 |
| Zhang, YP | 2 |
| Yan, HZ | 1 |
| Zhu, XF | 1 |
| Gong, XW | 1 |
| Jin, L | 1 |
| Wang, PP | 1 |
| Liu, YZ | 1 |
| Liang, YJ | 1 |
| Xue, M | 1 |
| Zhang, L | 3 |
| Yang, MX | 1 |
| Zhang, W | 1 |
| Li, XM | 1 |
| Ou, ZM | 1 |
| Li, ZP | 1 |
| Liu, SH | 1 |
| Li, XJ | 1 |
| Yang, SY | 1 |
| Wang, C | 1 |
| Wu, W | 1 |
| Kong, WJ | 2 |
| He, Q | 1 |
| Mei, D | 1 |
| Sha, S | 1 |
| Fan, S | 1 |
| Dong, M | 1 |
| Zhou, JY | 1 |
| Zhou, SW | 1 |
| Zhang, KB | 1 |
| Tang, JL | 1 |
| Guang, LX | 1 |
| Ying, Y | 1 |
| Xu, Y | 1 |
| Li, DD | 1 |
| Wei, J | 1 |
| Zuo, ZY | 1 |
| Wang, YM | 1 |
| Song, DQ | 1 |
| You, XF | 1 |
| Zhao, LX | 1 |
| Pan, HN | 1 |
| Kim, WS | 1 |
| Lee, YS | 1 |
| Cha, SH | 1 |
| Jeong, HW | 1 |
| Choe, SS | 1 |
| Lee, MR | 1 |
| Oh, GT | 1 |
| Park, HS | 1 |
| Lee, KU | 1 |
| Lane, MD | 1 |
| Kim, JB | 1 |
| Fei, J | 1 |
| Jiang, M | 1 |
| Zhu, H | 1 |
| Lu, D | 1 |
| Hu, SP | 1 |
| Xie, WN | 1 |
| Li, N | 1 |
| Ji, GY | 1 |
| Qiao, NL | 1 |
| Lin, XF | 1 |
| Chen, TY | 1 |
| Liu, HT | 1 |
| Xing, LJ | 1 |
| Liu, T | 1 |
| Hua, YQ | 1 |
| Zheng, PY | 1 |
| Ji, G | 1 |
| Xie, X | 1 |
| Meng, X | 1 |
| Zhou, X | 1 |
| Shu, X | 1 |
| Kong, H | 1 |
3 trials available for berberine and Fatty Liver
| Article | Year |
|---|---|
Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: a double-blind, randomized, cross-over clinical trial.
Topics: Adult; Aged; Berberine; Chlorogenic Acid; Cross-Over Studies; Dietary Supplements; Double-Blind Meth | 2015 |
Combination of simvastatin with berberine improves the lipid-lowering efficacy.
Topics: Animals; Berberine; Cholesterol, LDL; Drug Synergism; Drug Therapy, Combination; Fatty Liver; Humans | 2008 |
[Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease].
Topics: Adult; Alanine Transaminase; Berberine; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Fatty Live | 2011 |
17 other studies available for berberine and Fatty Liver
| Article | Year |
|---|---|
Berberine Ameliorates Abnormal Lipid Metabolism via the Adenosine Monophosphate-Activated Protein Kinase/Sirtuin 1 Pathway in Alcohol-Related Liver Disease.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Ethanol; Fatty Liver; Leukemia, Myeloid, Acute; L | 2023 |
Berberine protects steatotic donor undergoing liver transplantation via inhibiting endoplasmic reticulum stress-mediated reticulophagy.
Topics: Animals; Autophagosomes; Autophagy; Berberine; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; | 2019 |
Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21.
Topics: Animals; Autophagy; Berberine; Diet, Carbohydrate Loading; Diet, High-Fat; Energy Metabolism; Fatty | 2018 |
Berberine Modulates Gut Microbiota and Reduces Insulin Resistance via the TLR4 Signaling Pathway.
Topics: Animals; Berberine; Blood Glucose; Cholesterol, LDL; Diet, High-Fat; Disease Models, Animal; Drugs, | 2018 |
Berberine induces miR-373 expression in hepatocytes to inactivate hepatic steatosis associated AKT-S6 kinase pathway.
Topics: Berberine; Cell Line, Tumor; Fatty Liver; HEK293 Cells; Hep G2 Cells; Hepatocytes; Humans; Liver; Mi | 2018 |
Berberine Protects against NEFA-Induced Impairment of Mitochondrial Respiratory Chain Function and Insulin Signaling in Bovine Hepatocytes.
Topics: Animals; Berberine; Cattle; Cells, Cultured; Electron Transport; Fatty Acids, Nonesterified; Fatty L | 2018 |
Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids.
Topics: 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide); 3T3-L1 Cells; Adipocytes; Adipose Tissue, White; | 2019 |
Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Biopsy; Fatty Liver; Glucose Tolerance Test; Hep | 2019 |
[Intervention of berberine on lipid deposition in liver cells of non-alcoholic fatty liver disease rats induced by high fat diet].
Topics: Animals; Berberine; Diet, High-Fat; Down-Regulation; Drugs, Chinese Herbal; Fatty Liver; Hepatocytes | 2015 |
Berberine-loaded solid lipid nanoparticles are concentrated in the liver and ameliorate hepatosteatosis in db/db mice.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Berberine; Body Weight; Carnitine O-Palm | 2015 |
The Compound of Mangiferin-Berberine Salt Has Potent Activities in Modulating Lipid and Glucose Metabolisms in HepG2 Cells.
Topics: Adenylate Kinase; Berberine; Carnitine O-Palmitoyltransferase; Cell Death; Cell Survival; Enzyme Act | 2016 |
ERK-dependent mTOR pathway is involved in berberine-induced autophagy in hepatic steatosis.
Topics: Animals; Autophagy; Berberine; Body Weight; Cell Line; Diet, High-Fat; Disease Models, Animal; Extra | 2016 |
Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Chemical and Drug Induced Liver Injury; Diabetes Mel | 2008 |
Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity.
Topics: Adenylate Kinase; Animals; Berberine; Cells, Cultured; Diabetes Mellitus, Experimental; Drug Evaluat | 2009 |
Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats.
Topics: Amino Acid Sequence; Animals; Base Sequence; Berberine; Carrier Proteins; Diet; Dietary Fats; DNA Me | 2010 |
Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-alcoholic fatty liver disease in rats.
Topics: Animals; Berberine; Cholesterol; Disease Models, Animal; Fatty Liver; Gene Expression Regulation; Io | 2011 |
Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver.
Topics: Animals; Berberine; Fatty Liver; Gene Expression Regulation; Humans; Hypoglycemic Agents; Insulin Re | 2011 |